Maintenance pembrolizumab dose study for non-squamous lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 3 trial tests two maintenance schedules (“usual” dose versus a lower dose) of pembrolizumab after your initial chemotherapy with pembrolizumab. It aims to see if the lower dose works well enough to control cancer while possibly reducing side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-squamous non-small cell lung cancer that has been confirmed by biopsy or fluid test.
- Your cancer is stage III (not removable with surgery or not treatable with radiation) or stage IV.
- You finished 3 or 4 cycles of induction treatment with pembrolizumab plus platinum chemotherapy (cisplatin or carboplatin) and pemetrexed.
- After induction, your cancer is responding or stable (not getting worse) based on standard scan rules used in trials.
- If you have an EGFR, ALK, or ROS1 tumor change, you must have already had at least one targeted therapy.
- You must be at least 18 years old and healthy enough for treatment (performance status 0–1), and blood/organ tests must meet safety limits (including kidney and liver levels).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving immune therapy maintenance for a shorter time helps people with stage IV non-small cell lung cancer (NSCLC) who are doing well after initial chemo-immunotherapy. It aims to keep the cancer controlled while possibly reducing treatment exposure and side effects.
This Phase 1 study tests pembrolizumab (an immunotherapy) given together with a chemotherapy drug to treat non-small cell lung cancer that is locally advanced or has spread. It’s aimed at people who can handle treatment with an ECOG performance status of 2, including some with certain types of brain metastases.
This Phase 2 trial studies pembrolizumab (an immunotherapy drug) in people with advanced non-small cell lung cancer whose disease can’t be treated with curative surgery or combined chemoradiation. It aims to see how well the treatment works and how safely it can be given, especially for people who have not had other cancer medicines for metastatic disease.
This trial tests whether continuing treatment with cabozantinib plus pembrolizumab after your metastatic squamous lung cancer responds (or is stable) can help people live longer and stay in control. It may be an option if your cancer has already shown it can respond to initial (first-line) treatment.
This study examines how pembrolizumab (an immunotherapy drug) works in your body and how it affects your tumor, especially when combined with chemotherapy afterward. You'll be enrolled if your cancer has grown despite pembrolizumab treatment, and researchers will take blood samples and possibly a small tissue sample to understand why adding chemotherapy next might help.
This Phase 1/2 study tests pembrolizumab (an immune-based cancer treatment) either alone or with chemotherapy in people newly diagnosed with stage IV non-small cell lung cancer (NSCLC). It looks at how well the treatments work and whether they are safe, especially in people who haven’t had treatment yet for metastatic disease.
Hear when a new Metastatic Non-squamous Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.